GWPH News and Press, GW Pharmaceuticals Plc From 02/27/20

February 27, 2020 Palm Beach, FL – February 27, 2020 — The European CBD market has big potential says a new survey from New Frontier Data .  In fact, they found that Europe has a growing consumer base that has very positive views on CBD.  Per feedback from 3...

The magic mushroom story has only just begun. All thanks to evidence it can help treat a range of psychological issues, including PTSD, addition, eating disorders, depression, and even anxiety. There are even claims mushrooms can even “increase immune resistance to viral and bacteria...

Zogenix ( ZGNX ) had announced results from its phase 3 study treating patients with Lennox-Gastaut Syndrome (LGS). The primary endpoint of the study was met , however, investors were disappointed in that they expected the reduction of monthly seizures to be greater than what was report...

Oppenheimer says it continues to view GW Pharmaceuticals favorably ( GWPH -6.3% ) even after yesterday's profit  miss. More news on: GW Pharmaceuticals plc, Healthcare stocks news, Read more ...

SmileDirectClub (NASDAQ: SDC )  -24%  on Q4 earnings . More news on: SmileDirectClub, Inc., Spherix Incorporated, Fossil Group, Inc., Stocks on the move, , Read more ...

You might think that skyrocketing sales would translate to tremendous share price appreciation. But that wasn't the case for GW Pharmaceuticals (NASDAQ: GWPH) in 2019. The stock finished the year up only 7% while the S&P 500 index soared close to 29%. However, GW has gotten off to a bett...

Image source: The Motley Fool. GW Pharmaceuticals PLC   (NASDAQ: GWPH) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading

GW Pharmaceuticals plc (GWPH) Q4 2019 Results Earnings Conference Call February 25, 2020, 04:30 PM ET Company Participants Stephen Schultz - Vice President, Investor Relations Justin Gover - Chief Executive Officer Darren Cline - U.S. Chief Commercial Officer Chris Tovey - Chie...

GW Pharmaceuticals (NASDAQ: GWPH) announced its fourth quarter and full year financial results Tuesday afternoon. Although the company ended up missing the earnings target set by Wall Street, GW Pharma did manage to handily beat analysts' revenue expectations for the company. Fourth quarter...

GW Pharmaceuticals (NASDAQ: GWPH ) Q4 net loss of $24.9M, or 7 cents per share, narrows from net loss of $71.9M, or 20 cents per share, in the year-ago quarter. More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Read more ...